ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	70.97	210.52	60.06	386.92	10.53
Short-Term Investments	157.39	63.86	0	0	0
Cash & Cash Equivalents	228.36	274.38	60.06	386.92	10.53
Cash Growth	-16.77%	356.82%	-84.48%	3575.84%	-49.66%
Other Current Assets	3.37	3.32	0.67	3.74	0
Total Current Assets	231.73	277.7	60.73	390.66	10.53
Property, Plant & Equipment	0.82	0.77	0.69	3.8	4.57
Other Long-Term Assets	0.64	2.96	0.02	0.35	0.55
Total Long-Term Assets	1.46	3.74	0.72	4.15	5.12
Total Assets	233.19	281.44	61.45	394.8	15.65
Accounts Payable	2.15	4.93	3.11	2.58	3.52
Deferred Revenue	0	0.28	1.46	0	0
Current Debt	0.24	0.23	3.62	1.74	12.3
Other Current Liabilities	0	0	0	5.28	2.11
Total Current Liabilities	2.39	5.44	8.19	9.6	17.93
Long-Term Debt	0.04	0.25	5.41	2.33	3.32
Other Long-Term Liabilities	0	2.85	3.08	0	0
Total Long-Term Liabilities	0.04	3.11	8.49	2.33	3.32
Total Liabilities	2.43	8.55	16.68	11.93	21.25
Total Debt	0.27	0.48	9.03	4.07	15.62
Debt Growth	-43.04%	-94.68%	122.16%	-73.97%	101.97%
Retained Earnings	-131.3	-76.94	-42.26	-96.73	-63.79
Comprehensive Income	0.05	0.41	0	0	0
Shareholders' Equity	230.76	272.89	-31.27	382.88	-58.78
Net Cash / Debt	228.09	273.9	51.03	382.85	-5.09
Net Cash / Debt Growth	-16.73%	436.74%	-86.67%	-	-
Net Cash Per Share	2.40	6.86	1.77	131.68	-7.71
Working Capital	229.34	272.26	52.54	381.06	-7.4
Book Value Per Share	2.42	6.83	-1.08	131.68	-88.94

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).